Iqvia Holdings (IQV) Depreciation & Amortization (CF) (2012 - 2026)
Iqvia Holdings' (IQV) quarterly Depreciation & Amortization (CF) came in at $292.0 million in Q2 2026, up 5.8% year-over-year from $276.0 million in Q2 2025, and up 1.39% quarter-over-quarter from $288.0 million in Q1 2026.
Analysis
Iqvia Holdings (IQV) Depreciation & Amortization (CF) (2012 - 2026) Analysis & Trends
Iqvia Holdings has disclosed Depreciation & Amortization (CF) across 15 years of filings, most recently posting $292.0 million for Q2 2026.
- In Q2 2026, Depreciation & Amortization (CF) rose 5.8% year-over-year to $292.0 million; the TTM figure through Jun 2026 stood at $1.2 billion (up 5.44% YoY), while the FY2025 annual figure was $1.1 billion, up 2.69% from the prior year.
- Depreciation & Amortization (CF) came in at $292.0 million for Q2 2026 at Iqvia Holdings, up from $288.0 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $357.0 million in Q4 2022 to a low of $248.0 million in Q3 2022.
- Average Depreciation & Amortization (CF) over 5 years is $282.9 million, with a median of $277.0 million recorded in 2024.
- The largest YoY upside for Depreciation & Amortization (CF) was 36.26% in 2022 against a maximum downside of 26.19% in 2022.
- Over 5 years, Depreciation & Amortization (CF) stood at $357.0 million in 2022, then slipped by 11.48% to $316.0 million in 2023, then slipped by 4.11% to $303.0 million in 2024, then grew by 4.62% to $317.0 million in 2025, then fell by 7.89% to $292.0 million in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $292.0 million in Q2 2026, $288.0 million in Q1 2026, and $317.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | 292.00 Mn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | - |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | 90.77 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | 67.29 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | 19.60 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | 12.32 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | 314,000.00 |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | 190,775.50 |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | 40,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 292.00 Mn |
| Mar 31, 2026 | 288.00 Mn |
| Dec 31, 2025 | 317.00 Mn |
| Sep 30, 2025 | 286.00 Mn |
| Jun 30, 2025 | 276.00 Mn |
| Mar 31, 2025 | 265.00 Mn |
| Dec 31, 2024 | 303.00 Mn |
| Sep 30, 2024 | 278.00 Mn |
| Jun 30, 2024 | 269.00 Mn |
| Mar 31, 2024 | 264.00 Mn |
| Dec 31, 2023 | 316.00 Mn |
| Sep 30, 2023 | 297.00 Mn |
| Jun 30, 2023 | 259.00 Mn |
| Mar 31, 2023 | 253.00 Mn |
| Dec 31, 2022 | 357.00 Mn |
| Sep 30, 2022 | 248.00 Mn |
| Jun 30, 2022 | 270.00 Mn |
| Mar 31, 2022 | 255.00 Mn |
| Dec 31, 2021 | 262.00 Mn |
| Sep 30, 2021 | 336.00 Mn |